Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lytix Biopharma AS ( (DE:6BG) ) has shared an announcement.
Lytix Biopharma has reported robust clinical results for Q4 2024, highlighting the efficacy of their lead candidate LTX-315, particularly in treating basal cell carcinoma with a 97% response rate. With plans to discuss Phase III trials with the FDA in 2025, and ongoing studies in melanoma, Lytix is poised for significant advancements. The company has fortified its financial position, raising NOK 111 million to support upcoming milestones, enhancing their strategic position in the biotech industry.
More about Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company utilizing novel technology derived from host-defense peptide molecules. Their flagship product, LTX-315, is an oncolytic molecule aimed at boosting anti-cancer immunity, with applications across various cancer treatments.
YTD Price Performance: -2.08%
Average Trading Volume: 2,166
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €33.76M
For a thorough assessment of 6BG stock, go to TipRanks’ Stock Analysis page.